Quantitative BioImaging Laboratory (QBIL)
Welcome to the Quantitative BioImaging Laboratory (QBIL) at Emory University School of Medicine. We envision that QBIL will be a leading force in a new era of personalized medicine where quantitative methods of engineering and systems sciences have a pivotal role in disease detection, diagnostics, and treatment. The mission of the QBIL is to shape and advance the science and technology of biomedical imaging through innovative research and inspiring education, with the goal of becoming a destination laboratory internationally recognized as a first choice of both researchers and students. At QBIL, our faculty members, researchers and students play leading roles from basic science discovery to the creation, clinical evolution, and commercialization of new technologies, devices and therapies. QBIL is committed to excellence in scholarship and to the training of the next generation of imaging scientists. QBIL serves the community through advanced innovation, translational research and clinical application of imaging sciences.
Advances in molecular medicine offer the potential to move beyond traditional cytotoxic anticancer treatments and to develop safer and more effective targeted therapies based on the molecular characteristics of a patient’s tumor. Significant translational research efforts are needed to realize these emerging opportunities. There are urgent needs to develop quantitative imaging methods and clinical decision software tools. Such quantitative imaging may require the use of multiple imaging modalities. The development of anatomical, functional, and molecular imaging methods requires proper recognition and management of the complexities associated with the expression of suspected biomarkers. A full understanding of the response patterns for the potential surrogate biomarkers, e.g. those used to monitor angiogenesis, hypoxia, and necrosis, may often require the use of modeling and/or multiparametric analysis of the image data in order to examine quantitative correlations with other clinical metadata and clinical outcomes. These requirements generally hold for the measurements of responses to drugs or radiation therapy and for image-guided interventions.
Our research concentrates on the development and application of quantitative imaging technologies. Specifically, we are interested in synthesizing the information obtained from multiple imaging modalities and sources in order to study disease mechanisms and/or to aid in making clinical decisions. Our research goals are to (1) provide efficient methods and procedures for mapping the properties of tissue in space and time, (2) integrate multiple information streams acquired from different imaging technologies into a single coherent picture, and (3) validate and interpret in vivo imaging data for biologic, physiologic, and pathologic interpretation. The research will combine multimodality imaging and multidimensional data to exploit our current knowledge of the genetic and molecular bases of various diseases and therefore to have substantial positive implications for disease prevention, detection, diagnosis, and therapy.
Baowei Fei, PhD, EngD
Georgia Cancer Coalition Distinguished Scholar
Director, Quantitative BioImaging Laboratory
Dr. Baowei Fei was named as a Distinguished Investigator by the Academy of Radiology Research at the 2013 Annual Meeting of the RSNA.
The award is to recognize individuals for their accomplishments in imaging research. The program is intended to especially encourage those who have achieved scientific excellence while still being involved in clinical care, but it is not limited to clinician scientists only. Recipients of this award will become a member of the Council of Distinguished Investigators of the Academy of Radiology Research. The Academy of Radiology Research is an alliance of 28 professional imaging societies. Established in 1995, the Academy was the catalyst for creating the National Institute of Biomedical Imaging and Bioengineering (NIBIB), for supporting its growth and development, for accelerating investment in vital imaging research areas by other NIH institutes, and for building support for radiology and imaging in Congress and the Executive Branch. The Academy is the umbrella organization to the Coalition for Imaging and Bioengineering Research (CIBR) and the Academic Council (ARRAC).
Dr. Baowei Fei received the Outstanding Investigator Award from the Department of Radiology and Imaging Sciences of Emory University School of Medicine.
The award is to recognize a faculty member who has made outstanding contributions to the field within the last two years in the Department of Radiology and Imaging Sciences. The Award was made by the Awards Committee of the Emory Department of Radiology and Imaging Sciences, which includes both internal and external members. The awards will only be presented if qualified candidates are nominated. One of the 180 faculty members in the Department receives this Award in a year. Awards may not be given in all years.
Dr. Baowei Fei served in an AAPM Technology Assessment Committee - Work Group on Image-Guided Interventions
The American Association of Physicists in Medicine (AAPM) is a scientific, educational, and professional organization of medical physicists. The AAPM promotes the application of physics to medicine and biology, and encourages interest and training in medical physics and related fields. The AAPM has convened a task group on robotic-assisted interventions, which is coordinated by the Cancer Imaging Program of the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
Dr. Baowei Fei was invited to participate in the Department of Defense (DOD) Study Section.
Dr. Fei was invited to participate in the DOD Study Section of the Prostate Cancer Research Program. The Prostate Program prioritizes research that will 1) develop better tools to detect clinically relevant disease in asymptomatic men, 2) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, and 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
Dr. Baowei Fei's research on prostate biopsy is featured on the cover of Diagnostic Imaging Europe
In the January issue of Diagnostic Imaging Europe (DI Europe), the QBIL paper entitled “PET directed, 3D ultrasound-guided prostate biopsy” made the cover of the magazine that is published by DI Europe Ltd., an independent European-based publishing house. DI Europe is distributed to approximately 17,000 readers throughout Europe; it is published eight times a year and covers all the main imaging topics and sub-specialties. The readers are all clinicians or medical professionals in the radiology/medical imaging field.
Dr. Baowei Fei was invited to participate the NIH Biomedical Imaging Technology (BMIT) Study Section.
Dr. Fei was invited to participate the NIH Biomedical Imaging Technology (BMIT) Study Section. The BMIT Study Section reviews grant applications involving basic, applied, and pre-clinical aspects of the design and development of medical imaging system technologies, their components, software, and mathematical methods for studies at the cellular, organ, small or large animal, and human scale.